Hua Li

Hua Medicine is a leading clinical-stage biotechnology company based in Shanghai, China, focused on developing novel therapies for patients with unmet medical needs, particularly in metabolic and neurological disorders. The company is best known for developing dorzagliatin (HuaTangNing), a first-in-class glucokinase activator (GKA) that was approved in China in 2022 for the treatment of Type 2 diabetes. Hua Medicine utilizes a unique 'homeostasis' approach to drug discovery, aiming to restore the body's natural glucose-sensing capabilities. The company has established strategic partnerships with global leaders like Bayer for the commercialization of its products in China and continues to expand its pipeline into indications such as diabetic kidney disease and Alzheimer's disease.